Salvi Samanta, Casadio Valentina
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Methods Mol Biol. 2019;1909:201-209. doi: 10.1007/978-1-4939-8973-7_15.
Urine could be a convenient source of biomarkers for different diseases and clinical applications, mostly for cancer diagnosis, prognosis, treatment monitoring, and prenatal diagnosis. The ultra-noninvasive sampling and the possibility to analyze large volume are the main undisputed advantages of urine-based protocols. Recent and comprehensive studies showed that urinary cell-free DNA (ucfDNA) is informative to identify the genomic signature of patients, resulting in a huge tool to track the tumor evolution and for personalized medicine in urological and non-urological cancer.In this chapter, we reported the main published evidences on ucfDNA, with the aim at discussing its promising and translatable role in clinical practices.
尿液可能是不同疾病和临床应用中生物标志物的便捷来源，主要用于癌症诊断、预后、治疗监测和产前诊断。超非侵入性采样以及分析大量样本的可能性是基于尿液的检测方案的主要无可争议的优势。最近的全面研究表明，尿游离DNA（ucfDNA）有助于识别患者的基因组特征，从而成为追踪肿瘤进展以及用于泌尿和非泌尿癌症个性化医疗的强大工具。在本章中，我们报告了关于ucfDNA的主要已发表证据，旨在讨论其在临床实践中具有前景和可转化的作用。
